Stay updated with breaking news from Complete Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CRISPR Therapeutics shares traded as high as $200 18 months ago, but today the share price is $62, and market cap valuation $4.75bn. Read about CRSP here.
PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed SubjectsPBCAR0191 Achieved Peak CAR T Cell Expansion Matching Data from Autologous CAR T Peak Expansion in Long Term Durable RespondersPBCAR19B CAR T Cell Manuf...
Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor...
FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept in Combination with Pembrolizumab SEATTLE, Wash., - May 24, 2022 - Alpine Immune... | May 24, 2022
Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of... | May 13, 2022